Amplification and overexpression of MYC, which encodes c-Myc, has been associated with SCLC sensitivity to Aurora kinase inhibitors and with a loss of neuroendocrine markers and the ASCL1-negative and NEUROD1-positive lineage of SCLC [2, 5, 8, 10], including an inverse correlation between MYC and ASCL1 expression in this dataset [24]. Here, ASCL1 is linked to small cell lung carcinoma.